Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis.
作者信息
Tzaridis Theophilos, Gepfner-Tuma Irina, Hirsch Sophie, Skardelly Marco, Bender Benjamin, Paulsen Frank, Schaub Christina, Weller Johannes, Schäfer Niklas, Herrlinger Ulrich, Tabatabai Ghazaleh
机构信息
Division of Neuro-Oncology, Department of Neurology and Center of Integrated Oncology, University Hospital Bonn, Bonn, Germany.
Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany.
出版信息
Neuro Oncol. 2019 Jul 11;21(7):954-955. doi: 10.1093/neuonc/noz071.
Abstract
摘要
相似文献
1
Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis.瑞戈非尼治疗晚期高级别胶质瘤：一项回顾性双中心分析
Neuro Oncol. 2019 Jul 11;21(7):954-955. doi: 10.1093/neuonc/noz071.
2
Regorafenib in patients with recurrent high-grade astrocytoma.瑞戈非尼治疗复发性高级别脑胶质瘤患者的疗效观察。
J Cancer Res Clin Oncol. 2019 Apr;145(4):1037-1042. doi: 10.1007/s00432-019-02868-5. Epub 2019 Feb 28.
3
A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.瑞戈非尼用于治疗携带第17外显子继发性突变的转移性和/或不可切除胃肠道间质瘤患者的II期试验。
Oncotarget. 2017 Jul 4;8(27):44121-44130. doi: 10.18632/oncotarget.17310.
4
Regorafenib: a newly approved drug for advanced hepatocellular carcinoma.瑞戈非尼：一种新获批用于晚期肝细胞癌的药物。
Future Oncol. 2017 Aug;13(19):1665-1668. doi: 10.2217/fon-2017-0237. Epub 2017 Jun 14.
5
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.瑞戈非尼作为中晚期肝细胞癌二线治疗药物的多中心、开放标签、Ⅱ期安全性研究。
Eur J Cancer. 2013 Nov;49(16):3412-9. doi: 10.1016/j.ejca.2013.05.028. Epub 2013 Jun 25.
6
Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.regorafenib 在转移性骨肉瘤成人患者中的疗效和安全性：一项非比较、随机、双盲、安慰剂对照、2 期研究。
Lancet Oncol. 2019 Jan;20(1):120-133. doi: 10.1016/S1470-2045(18)30742-3. Epub 2018 Nov 23.
7
Regorafenib in metastatic colorectal cancer.瑞戈非尼用于转移性结直肠癌
Clin Adv Hematol Oncol. 2012 May;10(5):324-5.
8
REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis.REGOSARC：瑞戈非尼对比安慰剂治疗多柔比星难治性软组织肉瘤——一项无进展或毒性症状的质量调整时间分析
Cancer. 2017 Jun 15;123(12):2294-2302. doi: 10.1002/cncr.30661. Epub 2017 Mar 10.
9
Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND).regorafenib 治疗难治性转移性胰腺癌患者的 II 期研究（RESOUND）。
Future Oncol. 2019 Dec;15(35):4009-4017. doi: 10.2217/fon-2019-0480. Epub 2019 Nov 20.
10
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.regorafenib 用于索拉非尼治疗后进展的肝细胞癌患者（RESORCE）：一项随机、双盲、安慰剂对照、3 期试验。
Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6.
引用本文的文献
1
Genome-wide CRISPR-Cas9 screens identify BCL family members as modulators of response to regorafenib in experimental glioma.全基因组CRISPR-Cas9筛选确定BCL家族成员为实验性胶质瘤中瑞戈非尼反应的调节因子。
Neuro Oncol. 2025 May 15;27(4):916-931. doi: 10.1093/neuonc/noae278.
2
Current status of precision oncology in adult glioblastoma.成人胶质母细胞瘤中精准肿瘤学的现状
Mol Oncol. 2024 Dec;18(12):2927-2950. doi: 10.1002/1878-0261.13678. Epub 2024 Jun 20.
3
Just a spoonful of metformin helps the medicine go down.仅需一匙二甲双胍，助您轻松服药。
J Clin Invest. 2024 Mar 15;134(6):e179144. doi: 10.1172/JCI179144.
4
Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma.曲磷酰胺与依托泊苷治疗进展性胶质母细胞瘤的可行性与耐受性
Neurooncol Adv. 2023 Jul 20;5(1):vdad090. doi: 10.1093/noajnl/vdad090. eCollection 2023 Jan-Dec.
5
Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?抗血管生成治疗恶性脑肿瘤：它还重要吗？
Curr Oncol Rep. 2023 Jul;25(7):777-785. doi: 10.1007/s11912-023-01417-1. Epub 2023 Apr 18.
6
Clinical activity of regorafenib in elderly patients with recurrent glioblastoma.瑞戈非尼在复发性胶质母细胞瘤老年患者中的临床活性。
Mol Clin Oncol. 2023 Jan 10;18(2):9. doi: 10.3892/mco.2023.2605. eCollection 2023 Feb.
7
Observational real-life study on regorafenib in recurrent glioblastoma: does dose reduction reduce toxicity while maintaining the efficacy?复发性胶质母细胞瘤中瑞戈非尼的观察性真实世界研究：减少剂量是否会降低毒性而保持疗效？
J Neurooncol. 2022 Nov;160(2):389-402. doi: 10.1007/s11060-022-04155-9. Epub 2022 Oct 30.
8
Regorafenib beyond the Second Line in Relapsed Glioblastoma: A Case Report and Literature Review.瑞戈非尼用于复发性胶质母细胞瘤二线以上治疗：一例病例报告及文献综述
Case Rep Oncol. 2022 Jun 27;15(2):642-647. doi: 10.1159/000524954. eCollection 2022 May-Aug.
9
Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity.瑞戈非尼治疗复发性高级别胶质瘤：一项单中心回顾性分析的可行性、疗效和毒性。
Neurosurg Rev. 2022 Oct;45(5):3201-3208. doi: 10.1007/s10143-022-01826-z. Epub 2022 Jun 20.
10
Efficacy and tolerability of regorafenib in pretreated patients with progressive CNS grade 3 or 4 gliomas.regorafenib 在预处理后进展性 CNS 3 级或 4 级胶质瘤患者中的疗效和耐受性。
J Neurooncol. 2022 Sep;159(2):309-317. doi: 10.1007/s11060-022-04066-9. Epub 2022 Jun 18.
本文引用的文献
1
Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.雷戈非尼对比洛莫司汀治疗复发性胶质母细胞瘤患者（REGOMA）：一项多中心、开放标签、随机、对照、2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):110-119. doi: 10.1016/S1470-2045(18)30675-2. Epub 2018 Dec 3.
2
Lomustine and Bevacizumab in Progressive Glioblastoma.洛莫司汀和贝伐珠单抗治疗进展性胶质母细胞瘤。
N Engl J Med. 2017 Nov 16;377(20):1954-1963. doi: 10.1056/NEJMoa1707358.
3
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.欧洲神经肿瘤学会（EANO）成人星形细胞瘤和少突胶质细胞瘤诊断和治疗指南。
Lancet Oncol. 2017 Jun;18(6):e315-e329. doi: 10.1016/S1470-2045(17)30194-8. Epub 2017 May 5.
4
Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.接受贝伐单抗治疗的复发性胶质母细胞瘤患者的预后因素。
J Neurooncol. 2016 Aug;129(1):93-100. doi: 10.1007/s11060-016-2144-7. Epub 2016 May 18.
5
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.贝伐珠单抗单药或洛莫司汀单药与贝伐珠单抗联合洛莫司汀治疗复发性胶质母细胞瘤患者的比较（BELOB 试验）：一项随机对照 2 期试验。
Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15.
6
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.regorafenib 单药治疗既往治疗的转移性结直肠癌（CORRECT）：一项国际、多中心、随机、安慰剂对照、3 期临床试验。
Lancet. 2013 Jan 26;381(9863):303-12. doi: 10.1016/S0140-6736(12)61900-X. Epub 2012 Nov 22.
Zotero 插件